Giant Cell Tumor of Bone: An Update.
Publication/Presentation Date
3-22-2021
Abstract
PURPOSE OF REVIEW: To highlight the new developments in the management of advanced giant cell tumor of bone, a rare locally aggressive benign tumor, which was traditionally managed with surgery alone by either curettage and local adjuvant therapy, wide resection, or marginal excision. Here, we review the current role of systemic therapy for management of locally advanced or metastatic giant cell tumor of bone (GCTB).
RECENT FINDINGS: The elucidation of the pathophysiology of giant cell tumor of bone, especially with regards to the role of nuclear factor kappa B ligand (RANKL), has led to the Food and Drug Administration (FDA) approval of denosumab in the management of locally advanced or metastatic GCTB. For advanced giant cell tumor where surgical resection alone can cause severe morbidity, the paradigm has shifted from local treatment alone to multidisciplinary management with the consideration of use of denosumab.
Volume
23
Issue
5
First Page
51
Last Page
51
ISSN
1534-6269
Published In/Presented At
Basu Mallick, A., & Chawla, S. P. (2021). Giant Cell Tumor of Bone: An Update. Current oncology reports, 23(5), 51. https://doi.org/10.1007/s11912-021-01047-5
Disciplines
Medicine and Health Sciences
PubMedID
33754215
Department(s)
Hematology-Medical Oncology Division
Document Type
Article